SCHEMBL16058501

SCHEMBL16058501

Cc1c(-c2ccc(C(=O)NCc3ccccc3)cc2)ccn(C(=O)O)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.52
▸ ROCK2 O75116 1/20 0.50
▸ RPS6KA5 O75582 1/20 0.50
▸ MAP4K4 O95819 1/20 0.50
▸ PRKCG P05129 1/20 0.50
▸ PRKACA P17612 1/20 0.50
▸ RPS6KB1 P23443 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ AKT1 P31749 1/20 0.50
▸ GSK3A P49840 1/20 0.50
▸ GSK3B P49841 1/20 0.50
▸ PRKX P51817 1/20 0.50
▸ PRKCD Q05655 1/20 0.50
▸ PRKG2 Q13237 1/20 0.50
▸ ROCK1 Q13464 1/20 0.50
▸ DYRK1A Q13627 1/20 0.50
▸ PRKG1 Q13976 1/20 0.50
▸ PKN2 Q16513 1/20 0.50
▸ CDC42BPA Q5VT25 1/20 0.50
▸ CLK4 Q9HAZ1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14975270 0.79 KDM4E (0.39) MAPK1ALDH1A1MEN1KMT2AKDM4E
SCHEMBL16058367 0.74 DHODH (0.43) RAB9AALDH1A1NPC1
SCHEMBL16057309 0.74 MCL1 (0.40) RAB9AALDH1A1NPC1MEN1KMT2A
SCHEMBL539059 0.73 EPHX2 (0.84) EGFRROCK2RPS6KA5MAP4K4PRKCG
SCHEMBL11900090 0.73 HDAC6 (0.85) EGFRROCK2RPS6KA5MAP4K4PRKCG
SCHEMBL178366 0.72 MAPK14 (0.75) RAB9ALMNAHDAC6HDAC2HDAC8
SCHEMBL14975255 0.71 COMT (0.42) HDAC2HDAC8HDAC4KDM4EPOLB
SCHEMBL16057293 0.70 MAPK1 (0.57) EGFRROCK2RPS6KA5MAP4K4PRKCG
Alcohol SCHEMBL8615549 0.70 HDAC6 (0.69) ROCK2RPS6KA5MAP4K4PRKCGPRKACA
SCHEMBL16058477 0.70 PGR (0.43) CLK4HDAC6HDAC2HDAC8TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 EGFR 1700/4885ROCK2 4259/4885RPS6KA5 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback